Skip to main content

Table 2 Number and text of the 8 statements with high consensus and agreement

From: Nationwide consensus on the clinical management of treatment-resistant depression in Italy: a Delphi panel

Number

Statement

8.

When treating a depressed patient who has failed to respond to two antidepressants, I do tend to add lithium first

10.

When treating a depressed patient who has failed to respond to two antidepressants, I believe the best option is to combine esketamine (if currently available or when available in my centre)

11.

I am satisfied with the efficacy of lithium and/or antipsychotics as augmentation therapies for patients with TRD

13.

After obtaining a satisfactory response to treatment in a patient with TRD, long-term maintenance of therapy is essential

14.

In my opinion most patients with TRD can be treated with esketamine nasal spray in a community outpatient setting, without difficulties

15.

Educational support for patients helps to make the best use of the therapeutic opportunity offered by esketamine nasal spray

16.

In my daily reality, I have adequate and sufficient resources (staff, logistics, facilities, etc.) to provide patients with TRD with the best possible care

17.

In my opinion there are aspects of professional responsibility that the clinician must take into consideration in order to prefer, when possible, drugs with approved clinical indications for patients with TRD